Amphastar Pharmaceuticals (AMPH) Debt to Equity: 2013-2025
Historic Debt to Equity for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $0.78.
- Amphastar Pharmaceuticals' Debt to Equity fell 4.31% to $0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.78, marking a year-over-year decrease of 4.31%. This contributed to the annual value of $0.82 for FY2024, which is 10.93% down from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Debt to Equity is $0.78, which was down 2.34% from $0.80 recorded in Q2 2025.
- Amphastar Pharmaceuticals' Debt to Equity's 5-year high stood at $1.07 during Q3 2023, with a 5-year trough of $0.08 in Q2 2021.
- In the last 3 years, Amphastar Pharmaceuticals' Debt to Equity had a median value of $0.82 in 2024 and averaged $0.79.
- Its Debt to Equity has fluctuated over the past 5 years, first soared by 616.19% in 2023, then decreased by 23.58% in 2024.
- Amphastar Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.17 in 2021, then decreased by 16.92% to $0.14 in 2022, then spiked by 542.83% to $0.92 in 2023, then declined by 10.93% to $0.82 in 2024, then dropped by 4.31% to $0.78 in 2025.
- Its Debt to Equity was $0.78 in Q3 2025, compared to $0.80 in Q2 2025 and $0.80 in Q1 2025.